Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil
Open Access
- 22 February 2025
- journal article
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 44, 101031
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Foundation for the National Institutes of Health (UL1 TR001085)
- National Center for Research Resources
- National Center for Advancing Translational Sciences (UL1 TR001085)
- Coalition for Epidemic Preparedness Innovations
This publication has 20 references indexed in Scilit:
- Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in IndonesiaThe Lancet Infectious Diseases, 2023
- Global impact of the first year of COVID-19 vaccination: a mathematical modelling studyThe Lancet Infectious Diseases, 2022
- A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccinesVaccine, 2022
- Booster doses for inactivated COVID-19 vaccines: if, when, and for whomThe Lancet Infectious Diseases, 2021
- Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational studyThe Lancet Infectious Diseases, 2021
- A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccineVaccine, 2021
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020
- Interval estimation for the difference between independent proportions: comparison of eleven methodsStatistics in Medicine, 1998